Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
NCT02471716
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
66
Enrollment
INDUSTRY
Sponsor class
Conditions
Pigmented Villonodular Synovitis
Tenosynovial Giant Cell Tumor
Interventions
BIOLOGICAL:
FPA008
Sponsor
Five Prime Therapeutics, Inc.